Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
135.78
-1.47 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
3 Monster Stocks in the Making
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
November 16, 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.
Via
InvestorPlace
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
November 15, 2023
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the
Via
Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
November 15, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
November 09, 2023
Analysts still expect some sizable returns from the stock.
Via
The Motley Fool
1 Gene Therapy Stock to Buy and Hold for the Long Haul
November 08, 2023
The biotech has what it takes to overcome recent obstacles.
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 02, 2023
Via
Benzinga
Why Sarepta Therapeutics Stock Is Crashing Today
October 31, 2023
There's a plot twist with Sarepta's disappointing clinical results.
Via
The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
November 08, 2023
Just because a stock is "on sale" doesn't inherently make it worth purchasing.
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
November 02, 2023
SRPT earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
October 31, 2023
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.
Via
Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
October 31, 2023
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 31, 2023
Via
Benzinga
Why Are Stocks Down Today?
October 31, 2023
Stocks are down today and investors wondering why have come to the right place as we have an answer to that question!
Via
InvestorPlace
Earnings Scheduled For November 1, 2023
November 01, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
Via
Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 31, 2023
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
BB Stock Alert: What to Know as BlackBerry Announces CEO Departure
October 31, 2023
BlackBerry stock is falling on Tuesday as investors in BB react to news of CEO John Chen departing from the company this week.
Via
InvestorPlace
US Stocks Fall; Pfizer Swings To Q3 Loss
October 31, 2023
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% to 32,845.12 while the NASDAQ fell 0.50% to 12,726.17....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?
October 31, 2023
Sarepta Therapeutics stock is dropping with heavy trading as SRPT investors take in the lackluster results from a Phase 3 clinical trial.
Via
InvestorPlace
Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
October 31, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company announced the receipt of the Nasdaq delisting...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 31, 2023
Via
Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...
Via
Benzinga
Exposures
Product Safety
Pinterest To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Tuesday
October 31, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
EMBARKNG On A New Label? New Sarepta DMD Data Leads To Old Debates
October 30, 2023
Sarepta released their Phase III EMBARK data that is actually consistent with my previous analysis that the drug likely works in younger patients but not older.
Via
Talk Markets
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy
October 30, 2023
The drug didn't meet its primary goal in the pivotal study, but it met secondary measures.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
October 27, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 25, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 24, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.